CD1a is a non-polymorphic, membrane-bound glycoprotein. It is structurally related to MHC class I molecules and forms a heterodimer by non-covalently associating with ß-microglobulin. Its defining structural feature is a highly hydrophobic antigen-binding groove containing narrow A’ and F’ pockets. These pockets act as a molecular “ruler,” specifically accommodating the hydrophobic hydrocarbon tails of lipid molecules while leaving the polar head groups exposed on the outer surface.
CD1a specializes in lipid antigen presentation to T-cell receptors (TCRs), bridging the innate and adaptive immune systems. It is constitutively expressed at exceptionally high levels on epidermal Langerhans cells and mucosal dendritic cells. Unlike other CD1 proteins, CD1a lacks an intracellular tyrosine-based sorting motif; it traffics directly from the Golgi to the plasma membrane and cycles through early recycling endosomes.
CD1a functions as a cutaneous sentinel. It presents a wide array of exogenous lipids (e.g., mycobacterial lipopeptides, plant-derived urushiol, pollen) and endogenous self-lipids (e.g., squalene, wax esters, fatty acids found in sebum). CD1a-restricted T cells recognize these complexes via an “absence of interference” or direct head-group binding mechanism, prompting the secretion of Th2, Th17, and Th22 cytokines to maintain skin homeostasis or initiate inflammation.
CD1a is a premier immunohistochemical marker in surgical pathology. It is used to definitively identify and diagnose Langerhans cell histiocytosis (LCH) and differentiate Langerhans cell tumors from other dendritic cell neoplasms or histiocytic disorders.
Hyperactivation of CD1a-restricted T cells drives the pathogenesis of atopic dermatitis, psoriasis, and allergic contact dermatitis (e.g., poison ivy rash). Consequently, CD1a inhibitors and targeted biologics are active areas of therapeutic research to dampen pathologic cutaneous inflammation.
CD1a expression density on tumor-infiltrating dendritic cells serves as a prognostic biomarker for survival outcomes in various human cancers.
References:
- Immunol. 143:1723-1730 (1989)
- Genet. 36:40-45 (2004).
- Nature 441:315-321 (2006)



Reviews
There are no reviews yet.